Estrella Immunopharma (ESLA) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed Quince Therapeutics (QNCX) over the past year, losing 67.9% versus a loss of 92.4%. Over five years, ESLA leads with a -95.8% price change compared with -99.8% for QNCX. Quince Therapeutics is the larger company by market cap ($29.9 million vs $18.2 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | QNCX |
|---|---|---|
| Share price | $0.4175 | $29.36 |
| Market cap | $18.16M | $29.86M |
| 1-day change | -0.43% | +9.88% |
| YTD return | -73.24% | -95.62% |
| 1-year return | -67.88% | -92.35% |
| 5-year return | -95.77% | -99.77% |
| EPS (TTM) | $-0.25 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $910.00 |
| 52-week low | $0.361 | $15.10 |
| Distance from 52-week high | -86.75% | -96.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2774.25% | +156.91% |
| Average volume | 38.61K | 28.83K |
| Shares outstanding | 43.50M | 1.02M |
| Employees | — | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESLA has outperformed QNCX by 24.5 percentage points over the past year.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Healthcare · Biotechnology
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Healthcare · Biotechnology · 38 employees
ESLA vs QNCX FAQ
Which is bigger, Estrella Immunopharma or Quince Therapeutics?
Quince Therapeutics (QNCX) is larger, with a market capitalization of $29.86M compared with $18.16M for Estrella Immunopharma (ESLA).
Which stock has performed better over the past year, ESLA or QNCX?
ESLA returned -67.88% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and Quince Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.